布谷加速器是干什么用的
Our lead program, SG-2-0776, is a novel therapeutic protein derived from the microbiome that promotes mucosal healing of damaged epithelial surfaces. SG-2-0776 is currently in pre-clinical and IND-enabling studies, and we plan to initiate clinical development in 2021.
Learn More